Try our beta test site
9 studies found for:    Lymphoma OR CLL | Copanlisib
Show Display Options
Rank Status Study
1 Terminated Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Condition: Lymphoma, Mantle-Cell
Intervention: Drug: Copanlisib (BAY80-6946)
2 Active, not recruiting Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large-Cell Lymphoma
Intervention: Drug: Copanlisib (BAY80-6946)
3 Recruiting Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma,Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab
4 Recruiting Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
Condition: Lymphoma Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
5 Recruiting Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
6 Active, not recruiting Copanlisib Pharmacodynamic Study
Condition: Non Hodgkin Lymphoma (NHL)
Intervention: Drug: Copanlisib (BAY80-6946)
7 Active, not recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (CHRONOS-1)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
8 Recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo
9 Not yet recruiting Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
Condition: Mature T-Cell and NK-Cell Neoplasm
Interventions: Drug: Copanlisib;   Drug: Gemcitabine

Study has passed its completion date and status has not been verified in more than two years.